GLENMARK PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Net Sales | Rs m | 89,731 | 90,458 | 0.8% |
Other income | Rs m | 374 | 914 | 144.6% |
Total Revenues | Rs m | 90,105 | 91,372 | 1.4% |
Gross profit | Rs m | 19,558 | 16,154 | -17.4% |
Depreciation | Rs m | 2,644 | 3,019 | 14.2% |
Interest | Rs m | 2,373 | 2,856 | 20.3% |
Profit before tax | Rs m | 14,914 | 11,193 | -24.9% |
Tax | Rs m | 3,827 | 3,155 | -17.6% |
Profit after tax | Rs m | 11,088 | 8,039 | -27.5% |
Gross profit margin | % | 21.8 | 17.9 | |
Effective tax rate | % | 25.7 | 28.2 | |
Net profit margin | % | 12.4 | 8.9 |
Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Networth | Rs m | 44,911 | 51,530 | 14.7 |
Current Liabilities | Rs m | 27,027 | 32,879 | 21.7 |
Long-term Debt | Rs m | 45,363 | 41,418 | -8.7 |
Total Liabilities | Rs m | 104,526 | 112,751 | 7.9 |
Current assets | Rs m | 68,746 | 69,887 | 1.7 |
Fixed Assets | Rs m | 35,780 | 42,864 | 19.8 |
Total Assets | Rs m | 104,526 | 112,751 | 7.9 |
Particulars | No. of months | 12 | 12 | % Change |
---|---|---|---|---|
Year Ending | Mar-17 | Mar-18 | ||
Cash Flow from Operating Activities | Rs m | 6,574 | 16,481 | 150.7% |
Cash Flow from Investing Activities | Rs m | -7,123 | -10,133 | - |
Cash Flow from Financing Activities | Rs m | 5,432 | -4,685 | - |
Net Cash Flow | Rs m | 1,992 | 1,770 | -11.2% |
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Sales per share (Unadj.) | Rs | 318.0 | 320.6 |
TTM Earnings per share | Rs | 39.3 | 28.5 |
Diluted earnings per share | Rs | 39.3 | 28.5 |
Price to Cash Flow | x | 17.6 | 18.5 |
TTM P/E ratio | x | 22.2 | 18.5 |
Price / Book Value ratio | x | 5.4 | 4.0 |
Market Cap | Rs m | 242,989 | 204,205 |
Dividends per share (Unadj.) | Rs | 2.0 | 2.0 |
Current Ratio: The company's current ratio deteriorated and stood at 2.1x during FY18, from 2.5x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.
Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 4.9x during FY18, from 7.3x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.
Return on Equity (ROE): The ROE for the company declined and down at 15.6% during FY18, from 24.7% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.
Return on Capital Employed (ROCE): The ROCE for the company declined and down at 15.1% during FY18, from 19.1% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.
Return on Assets (ROA): The ROA of the company declined and down at 9.7% during FY18, from 12.9% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Current ratio | x | 2.5 | 2.1 |
Debtors’ Days | Days | 98 | 94 |
Interest coverage | x | 7.3 | 4.9 |
Debt to equity ratio | x | 1.0 | 0.8 |
Return on assets | % | 12.9 | 9.7 |
Return on equity | % | 24.7 | 15.6 |
Return on capital employed | % | 19.1 | 15.1 |
To see how GLENMARK PHARMA has performed over the last 5 years, please visit here.
Over the last one year, GLENMARK PHARMA share price has moved down from Rs 857.8 to Rs 527.2, registering a loss of Rs 330.6 or around 38.5%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,157.6 (down 1.1%). Over the last one year it has moved down from 15,312.4 to 13,157.6, a loss of 2,155 points (down 14.1%).
Overall, the S&P BSE SENSEX is up 12.1% over the year.
(To know more, check out historical annual results for GLENMARK PHARMA and quarterly results for GLENMARK PHARMA)
GLENMARK PHARMA currently trades at Rs 1,025.2 per share. You can check out the latest share price performance of GLENMARK PHARMA here...
The revenues of GLENMARK PHARMA stood at Rs 91,372 m in FY18, which was up 1.4% compared to Rs 90,105 m reported in FY17.
GLENMARK PHARMA's revenue has grown from Rs 58,962 m in FY14 to Rs 91,372 m in FY18.
Over the past 5 years, the revenue of GLENMARK PHARMA has grown at a CAGR of 11.6%.
The net profit of GLENMARK PHARMA stood at Rs 8,039 m in FY18, which was down -27.5% compared to Rs 11,088 m reported in FY17.
This compares to a net profit of Rs 7,430 m in FY16 and a net profit of Rs 2,095 m in FY15.
Over the past 5 years, GLENMARK PHARMA net profit has grown at a CAGR of 10.2%.
The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.
This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.
The cash flow statement of GLENMARK PHARMA reveals:
Here's the cash flow statement of GLENMARK PHARMA for the past 5 years.
(Rs m) | FY14 | FY15 | FY16 | FY17 | FY18 |
---|---|---|---|---|---|
From Operations | 8,537 | 4,817 | 3,448 | 6,574 | 16,481 |
From Investments | -3,681 | -5,400 | -8,802 | -7,123 | -10,133 |
From Financial Activity | -980 | 1,992 | 6,986 | 5,432 | -4,685 |
Net Cashflow | 1,896 | -311 | 934 | 1,992 | 1,770 |
Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.
The ratio/financial analysis of GLENMARK PHARMA reveals:
Here's the ratio/financial analysis of GLENMARK PHARMA for the past 5 years.
FY14 | FY15 | FY16 | FY17 | FY18 | |
---|---|---|---|---|---|
Operating Profit Margin (%) | 18.5 | 15.6 | 19.2 | 21.8 | 17.9 |
Net Profit Margin (%) | 9.3 | 3.2 | 9.9 | 12.4 | 8.9 |
Debt to Equity Ratio (x) | 0.8 | 1.4 | 0.7 | 1.0 | 0.8 |
Read: Latest Annual Report Analysis of GLENMARK PHARMA
Equitymaster requests your view! Post a comment on "GLENMARK PHARMA 2017-18 Annual Report Analysis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!